J Gastrointestin Liver Dis, June 2017 Vol. 27 No 2: [189] [190] [191] [192] [193] [194] showed normal findings. Pneumotorax, pulmonary embolism and pneumonia were excluded. 5-ASA was reintroduced with a dose of 4000 mg and she was discharged. Figure 1 presents a brief illustration of the clinical course.
On current presentation, her abdomen was tender on palpation. The serum pancreatic amylase (295 U/L, normal: 28-100 U/L), and lipase levels (1455 U/L, normal: <60 U/L) were elevated. The levels of inflammatory parameters were increased with a C-reactive protein (CRP) value of 16 .60 mg/L (normal < 5 mg/L) and a white blood cell count of 41,300 G/L (normal: 4000-10000 G/L). On abdominal ultrasound the pancreas had normal echogenicity and echostructure, there were no stones in the gall bladder and no dilation of the common bile duct. A moderate wall thickening was present throughout the colon as a manifestation of Crohn's disease.
Acute pancreatitis (AP) was diagnosed, and the patient was treated according to the evidence-based practice guidelines [7, 8] . She was given intravenous hydration, early nasogastric tube feeding, intravenous drotaverine (40 mg), tramadol (50 mg) and metamizole (1000 mg) for pain management, and ondansetron (4 mg) for nausea. 5-ASA was discontinued immediately. She was not aware of any AP episodes before. No calcifications were detected in the pancreatic tissue on ultrasound. The serological tests showed a previous infection with Epstein-Barr Virus and the effect of vaccination against mumps and rubeola; active infections with CMV, Varicella-zoster, HIV1 and 2, Hepatitis A, B, and C, HHV and Adenovirus were excluded. No pathogenic PRSS1 mutations were found on genetic testing for predisposing factors of pancreatitis. Her calcium and triglyceride serum levels were in the reference range. No signs of vascular disease were found. No recent trauma occurred, and no surgical interventions or ERCP was performed. Hence, the diagnosis was idiopathic AP.
Amylase and lipase levels began to drop immediately after starting the treatment and the epigastric pain subsided on day two. Amylase level dropped to normal (45 IU/L), and the levels of lipase and inflammatory parameters progressively decreased. Since the first episode of AP was considered as idiopathic, the re-administration of 5-ASA on day four with one 4000 mg dose was performed as an unintentional rechallenge. At the same time, the diet of the patient was advanced to a reduced amount of nasogastric tube feeding combined with a small amount of solid food and liquid. Rechallenge resulted in recurrence of the epigastric pain after 8 hours and rapid elevation of pancreatic enzyme levels. The causal connection between the drug intake and AP was recognized, and drug-induced AP (DIAP) was diagnosed, the previous treatment was resumed and 5-ASA was permanently withdrawn. Repeat ultrasonography on day five was remarkable for a pancreas with slightly inhomogeneous, low echogenicity, consistent with acute inflammation (Fig. 2) . On day seven, pain subsided, diet was advanced uneventfully, pancreatic enzyme levels dropped to nearly normal values, and the patient was discharged.
Both AP episodes were considered clinically mild, in spite of the marked increase in the leucocyte count, which we considered a consequence of the steroid therapy. The bedside index of severity in acute pancreatitis (BISAP) score at presentation was 1 [10] . At the three-month follow-up, the patient had no recurrence of pancreatitis. Her Crohn's colitis symptoms are currently managed with budesonide and azathioprine. Magnetic resonance enterography four weeks after admission disclosed no involvement of the small bowel in Crohn's disease. Abdominal ultrasonography and magnetic resonance cholangiopancreatography (MRCP) performed five weeks after admission disclosed normal findings.
SYSTEMATIC REVIEW OF THE LITERATURE
We performed a systematic literature search on April 2017 on the databases PubMed, EMBASE and Web of Science with the search terms "5-ASA AND pancreatitis" with limitations of English language and human target, regardless of the date of publication (Fig. 3 ). Studies were included only if authors concluded that 5-ASA-derived medication was the most probable cause of the adverse drug reaction (ADR), meeting only one diagnostic criteria for AP according to the IAP/APA evidence-based guidelines, such as asymptomatic pancreatic enzyme level increase or abdominal pain. Thirtyfive manuscripts, including 42 patients [1] [2] [3] [4] [5] were identified applying this searching strategy (Table I ). The ratio female/male was 24/19. The mean age was 26.88±11.1 years; 9 patients were pediatric cases (under 18 years of age). Most of the identified patients treated with 5-ASA derived drugs were suffering from ulcerative colitis (67.4%, n=29) and Crohn's disease (23.3%, n=10). One case of regional enteritis and one of unspecific colitis were found, and there was no data concerning the condition in two cases. Sulfasalazine was responsible in 35.7% (n=30) for the ADRs. 5-ASA in pH-dependent coating, in time-dependent coating and in otherwise non specified form caused ADRs in 22.6% (n=19), 8.3% (n=7) and 22.6% (n=19) of the identified cases. 5-ASA in enema form and Olsalazine were shown to cause ADRs in 11.9% (n=10) and 4.8% (n=4).
DISCUSSION
The most common etiologies for AP are gallstones, biliary sludge or microlithiasis, alcohol, smoking, hypertriglyceridemia, post-ERCP status, hypercalcemia, genetic mutations, infections or toxins, trauma, pancreas divisum and vascular disease [41, 42] . The rest of the episodes are usually termed idiopathic. Drug-induced AP is rare and challenging to identify because it has no clinical features to distinguish it from the more common etiologies of AP [43] . Moreover, because it is unethical to intentionally rechallenge with the offending drug due to the potentially life-threatening nature of pancreatitis, in most cases it remains a speculative diagnosis made by exclusion.
A classification of drugs reported to cause AP was made by Badalov et al. in 2007 [43] , based on the published weight of evidence. Four classes of drugs were identified. Class Ia included drugs that previously had been described as positively rechallenged at least once, with all other etiologies ruled out. 5-ASA belonged to the class Ia category of drugs; nonetheless, cases with positive rechallenge and parallel exclusion of all other etiologies in the literature are still rare.
We analyzed the clinical course of 5-ASA-induced AP cases found on the systematic literature search. Hypersensitivity [1, 2, 11, 15, 37] and idiosyncrasy [1, 29] are usually thought to be involved in the pathogenic mechanism of 5-ASA-induced AP (according to 38.9% of the authors). In most of the identified cases, the reaction seemed not to be dose-dependent, however, the specific underlying mechanism remained a matter for speculation. We found one report of assumed dose-dependent toxicity [12] . The latency between intake of 5-ASA and onset of pancreatitis usually varied between a few days and a few months, however, DIAP can occur after long term treatment as well [4, 12, 21, 28, 35, 39] . The route of administration [4, 25, 29, 31 , 39] (either oral or rectal) and use of coated formulations [1] [2] [3] 17] (time-or pH-dependent) did not appear to affect the risk of AP, and in most of the cases, there was a rapid recurrence if rechallenged [3, 12, 14, 15, 18] . 5-ASA induced AP was usually self-limited. In almost half (47.6%) of the identified cases, there was no data concerning the imaging of the pancreas, and in 13.1%, the imaging examinations showed normal findings. The severity of AP and length of hospitalization were mostly not described by the authors. In the cases which reported severity, AP was usually mild (73.7%) [2, 5, 11, 19, 22, 25, 28, 38] , one moderately severe episode was found [31] , and of the four severe cases reported [4, 20, 32] , two were lethal; 60.5% of the identified patients (n=26) were rechallenged positively with one of the formulations of the 5-ASA. After discontinuation of the offending drug, symptoms usually disappeared quickly [3, 12, 14, 15, 18] , as observed in our case as well.
Our patient had no fever, no skin rash or peripheral eosinophilia, which would be suggestive of an allergic reaction: the pathogenic mechanism was probably an idiosyncratic reaction [44] , but hypersensitivity cannot be excluded. At presentation, medications were: 5-ASA for 41 days, metoprolol for three years, methylprednisolone for 13 days, pantoprazole for two weeks and potassium-chloride intermittently. We ruled out potassium chloride as the offending drug because it had never been suspected as a cause of AP. Metoprolol cannot be ruled out totally because it was previously noted to cause AP [45] in the literature. Our patient took metoprolol for three years without adverse events and during her entire hospitalization, including the time of pancreatic enzyme level normalization and symptomatic improvement. Few cases reported pantoprazole [46, 47] and methylprednisolone [48] [49] [50] [51] [52] [53] [54] induced AP, but in our patient, these drugs were continued throughout the hospital stay as well. Parallel to the rechallenge, our patient's diet was advanced, which could cause recurrence of AP. However, this is unlikely because repeated advancement two days later took place uneventfully.
Our patient's medical history strongly suggests that 5-ASA was the cause of her AP. We ruled out several other etiologies for AP (Table II) . Our case therefore reached a score of 8, probable causality on the Naranjo adverse drug reaction probability scale [55] .
CONCLUSION
Rechallenging with a drug which can be a possible cause of AP is ethically questionable and is usually not done because of the danger of recurrence of a potentially severe disease. Intentional rechallenge can be reasonable in rare cases if the drug is the only therapy of a life-threatening disease and readministration is probably worth taking the risk. In our patient, the causal relationship between the drug intake and the first mild AP episode was not recognized first, and the patient was diagnosed with idiopathic AP; consequently, an unintentional positive rechallenge occurred, which has the biggest weight of evidence in assessing causality in the course of DIAP.
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